Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market & Industry Briefs

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover new challenges to the medical imaging industry and to the efficacy of vertebroplasty procedures, final results from the MADIT-CRT trial, and new developments in the percutaneous heart valve replacement and repair market.

You may also be interested in...



Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.

Physicians and Industry Respond to Recent Vertebroplasty Studies

In August 2009, vertebral compression fracture treatment was dealt an unexpected blow when The New England Journal of Medicine published two articles that detailed prospective randomized controlled trials in which vertebroplasty did not result in a statistically significant clinical benefit over a sham procedure. The spinal community responded quickly to these articles, pointing out shortcomings of the two trials.

Physicians and Industry Respond to Recent Vertebroplasty Studies

In August 2009, vertebral compression fracture treatment was dealt an unexpected blow when The New England Journal of Medicine published two articles that detailed prospective randomized controlled trials in which vertebroplasty did not result in a statistically significant clinical benefit over a sham procedure. The spinal community responded quickly to these articles, pointing out shortcomings of the two trials.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel